Study summary
A slow-release bladder implant cleared tumors in 82% of people who had run out of options
82.4%complete response rate
What was tested
TAR-200 (Inlexzo), a small device placed in the bladder that releases gemcitabine for weeks at a time, for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
What they found
- 82.4% had a complete response; it lasted a median of 25.8 months.
- Warnings include bladder perforation and risks from delaying surgery.
What it means
Lets some people avoid having their bladder removed. Trials are now testing it earlier, against BCG itself.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.